Differences in local and systemic inflammatory markers in patients with obstructive airways disease

Primary Care Respiratory Journal

Volumn 20, Issue 4, 2011, Pages 407-413

  Tilemann, Lisa ^a   Gindner, Lena ^b   Meyer, Franz ^b   Szecsenyi, Joachim ^b   Schneider, Antonius ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Asthma; COPD; Diagnosis; Inflammatory markers; Local; Systemic

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN E;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EOSINOPHIL COUNT; FEMALE; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE AIRWAY DISEASE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT PARAMETERS; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 85027931224     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00069     Document Type: Article

References (31)

1. Bleecker ER. Similarities and differences in asthma and COPD. The Dutch hypothesis. Chest 2004;126(2 Suppl):93-5S. http://dx.doi.org/10.1378/chest.126.2_suppl_1.93S
2. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993;6(9):1368-70.
3. Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005;60(5):383-8. http://dx.doi.org/10.1136/thx.2004.031104
4. Ahmad Al Obaidi AH, Mohamed Al Samarai AG, Yahya Al Samarai AK, Al Janabi JM. The predictive value of IgE as biomarker in asthma. J Asthma 2008;45(8):654-63. http://dx.doi.org/10.1080/02770900802126958
5. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320(5):271-7. http://dx.doi.org/10.1056/NEJM198902023200502
6. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323(15):1033-9. http://dx.doi.org/10.1056/NEJM199010113231505
7. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004;59(7):574-80. http://dx.doi.org/10.1136/thx.2003.019588
8. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006;61(10):849-53. http://dx.doi.org/10.1136/thx.2006.059808
9. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107(11):1514-19. http://dx.doi.org/10.1161/01.CIR.0000056767.69054.B3
10. Qian FH, Zhang Q, Zhou LF, et al. High-sensitivity C-reactive protein: a predicative marker in severe asthma. Respirology 2008;13(5):664-9. http://dx.doi.org/10.1111/j.1440-1843.2008.01314.x
11. Takemura M, Matsumoto H, Niimi A, et al. High sensitivity C-reactive protein in asthma. Eur Respir J 2006;27(5):908-12.
12. Olafsdottir IS, Gislason T, Thjodleifsson B, et al. C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax 2005;60(6):451-4. http://dx.doi.org/10.1136/thx.2004.035774
13. Higashimoto Y, Yamagata Y, Taya S, et al. Systemic inflammation in chronic obstructive pulmonary disease and asthma: similarities and differences. Respirology 2008;13(1):128-33.
14. Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koëter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002;32(7):1096-103. http://dx.doi.org/10.1046/j.1365-2222.2002.01412.x
15. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006;100(11):1907-17. http://dx.doi.org/10.1016/j.rmed.2005.10.004
16. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005;172(4):453-9. http://dx.doi.org/10.1164/rccm.200411-1498OC
17. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Creactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175(3):250-5. http://dx.doi.org/10.1164/rccm.200605-713OC
18. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008;133(6):1336-43. http://dx.doi.org/10.1378/chest.07-2433
19. Gelb AF, Flynn TC, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006;129(6):1492-9. http://dx.doi.org/10.1378/chest.129.6.1492
20. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360(9347):1715-21. http://dx.doi.org/10.1016/S0140-6736(02)11679-5
21. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171(8):912-30. http://dx.doi.org/10.1164/rccm.200406-710ST
22. Deykin A, Halpern O, Massaro AF, Drazen JM, Israel E. Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am J Respir Crit Care Med 1998;157(3 Pt 1):769-75.
23. Schneider A, Tilemann L, Schermer T, et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement: results of a prospective diagnostic study. Respir Res 2009;10:15. http://dx.doi.org/10.1186/1465-9921-10-15
24. American Association for Respiratory Care. AARC Clinical Practice Guideline. Body plethysmography: 2001 revision and update. Respir Care 2001;46:506-13.
25. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161(1):309-29.
26. Papi A, Romagnoli M, Baraldo S, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162(5):1773-7.
27. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167(3):418-24. http://dx.doi.org/10.1164/rccm.200203-183OC
28. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005;127(2):558-64. http://dx.doi.org/10.1378/chest.127.2.558
29. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61(1):23-8. http://dx.doi.org/10.1136/thx.2005.042200
30. Arif AA, Delclos GL, Colmer-Hamood J. Association between asthma, asthma symptoms and C-reactive protein in US adults: data from the National Health and Nutrition Examination Survey, 1999-2002. Respirology 2007;12(5):675-82. http://dx.doi.org/10.1111/j.1440-1843.2007.01122.x
31. Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009;64:431-8. http://dx.doi.org/10.1111/j.1398-9995.2008.01855.x